BMPR2 and pulmonary arterial hypertension: Compared to BMPR2 mutation carriers and noncarriers (idiopathic PAH), ACVRL1 mutation carriers are diagnosed at a younger age and have a worse prognosis despite similar therapy and better haemodynamics at time of diagnosis [44].